Expanding the
Possibilities of
Drug Delivery

As therapies evolve beyond small molecules to include nucleic acids, peptides, proteins, and antibodies, drug delivery systems must adapt to new challenges. Traditional nanoparticles often face issues such as inconsistent dosing, limited administration routes, frequent dosing requirements, unwanted side effects, and constraints on the types of molecules they can carry. These limitations impact both treatment efficacy and patient experience. Addressing them requires innovative approaches that enhance stability, targeting precision, and bioavailability—unlocking new potential for therapeutic delivery.

The Phoreus Biotech Approach: Peptide Nanoparticles (PNPs)

Phoreus Biotech is developing next-generation Peptide Nanoparticles (PNPs) to address these longstanding drug delivery challenges. Engineered from self-assembling peptide sequences, our PNPs are designed to form stable, biocompatible nanostructures that offer flexibility across multiple therapeutic applications. By advancing this technology, we aim to improve drug stability, enhance targeting capabilities, and expand treatment possibilities—moving beyond the constraints of conventional carriers.

Key Features of PNPs:

PNPs are designed to encapsulate and deliver a range of therapeutic molecules, including small molecules, proteins, nucleic acids, and peptides—offering potential for diverse treatment applications.

A modular design enables the integration of targeting ligands and stimuli-responsive features, with the goal of enhancing drug specificity and reducing off-target effects.

PNPs are designed to minimize immune responses and toxicity, addressing common issues seen with lipid-based carriers.

PNPs offer the potential for less invasive routes of drug delivery, such as:

  • Buccal (oral mucosal) 
  • Transdermal (patch-based) 
  • Pulmonary (inhalable)

Work With Us

Contact us to learn more about partnership opportunities or cell transfection kits.

Contact Us